1.0Law.asiahttps://law.asia/zh-hans/rich600338<blockquote class="wp-embedded-content"><a href="https://law.asia/zh-hans/biopharma-fundraising-remain-hot/">香港生物制药领域融资持续火热</a></blockquote> <script type='text/javascript'> <!--//--><![CDATA[//><!-- /*! This file is auto-generated */ !function(d,l){"use strict";var e=!1,n=!1;if(l.querySelector)if(d.addEventListener)e=!0;if(d.wp=d.wp||{},!d.wp.receiveEmbedMessage)if(d.wp.receiveEmbedMessage=function(e){var t=e.data;if(t)if(t.secret||t.message||t.value)if(!/[^a-zA-Z0-9]/.test(t.secret)){for(var r,i,a,s=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),n=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),o=new RegExp("^https?:$","i"),c=0;c<n.length;c++)n[c].style.display="none";for(c=0;c<s.length;c++)if(r=s[c],e.source===r.contentWindow){if(r.removeAttribute("style"),"height"===t.message){if(1e3<(a=parseInt(t.value,10)))a=1e3;else if(~~a<200)a=200;r.height=a}if("link"===t.message)if(i=l.createElement("a"),a=l.createElement("a"),i.href=r.getAttribute("src"),a.href=t.value,o.test(a.protocol))if(a.host===i.host)if(l.activeElement===r)d.top.location.href=t.value}}},e)d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",t,!1),d.addEventListener("load",t,!1);function t(){if(!n){n=!0;for(var e,t,r=-1!==navigator.appVersion.indexOf("MSIE 10"),i=!!navigator.userAgent.match(/Trident.*rv:11\./),a=l.querySelectorAll("iframe.wp-embedded-content"),s=0;s<a.length;s++){if(!(e=a[s]).getAttribute("data-secret"))t=Math.random().toString(36).substr(2,10),e.src+="#?secret="+t,e.setAttribute("data-secret",t);if(r||i)(t=e.cloneNode(!0)).removeAttribute("security"),e.parentNode.replaceChild(t,e)}}}}(window,document); //--><!]]> </script><iframe sandbox="allow-scripts" security="restricted" src="https://law.asia/zh-hans/biopharma-fundraising-remain-hot/embed/" width="600" height="338" title="“香港生物制药领域融资持续火热” — Law.asia" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe>https://law.asia/wp-content/uploads/2020/03/drug-biopharm.jpg900600中国生物制药今年2月在香港联交所首次发行价值7.5亿欧元于2025年到期的零息可转换债券。法律专家就生物制药行业的前景表示乐观。“临床试验通常需要特别长的时间才能完成，而且成本可能会非常高，”参与此项目的天元律师事务所的合伙人甄月能告诉《商法》，“此次发行再次确认了香港作为全球生物制药公司主要融资中心的地位。”